Abstract

The invention relates to a process for the diagnosis and treatment of squamous cell carcinomas which is based on the expression of the variant exon v6 of the CD44-gene as a molecular target. In a preferred embodiment, v6-specific antibody molecules, particularly the monoclonal antibody BIWA-1 (VFF-18) is used for this purpose.